Condition
Acute Graft Versus Host Disease in Intestine
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Unknown2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04769895Phase 3Active Not RecruitingPrimary
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
NCT04768907UnknownPrimary
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
NCT04711967Not ApplicableUnknownPrimary
Prospective Study of FMT for Acute Intestinal GVHD After Allo-HSCT
Showing all 3 trials